Efficacy of different rituximab therapeutic strategies in patients with neuromyelitis optica spectrum disorders
- 1 November 2019
- journal article
- research article
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 36, 101430
- https://doi.org/10.1016/j.msard.2019.101430
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Treatment Outcomes With Rituximab in 100 Patients With Neuromyelitis OpticaJAMA Neurology, 2015
- Neuromyelitis optica spectrum disorders: long-term safety and efficacy of rituximab in Caucasian patientsMultiple Sclerosis Journal, 2015
- International consensus diagnostic criteria for neuromyelitis optica spectrum disordersNeurology, 2015
- Analysis of the treatment of neuromyelitis opticaJournal of the Neurological Sciences, 2015
- Update on the diagnosis and treatment of neuromyelitis optica: Recommendations of the Neuromyelitis Optica Study Group (NEMOS)Zeitschrift für Neurologie, 2013
- A 5-Year Follow-up of Rituximab Treatment in Patients With Neuromyelitis Optica Spectrum DisorderJAMA Neurology, 2013
- Does natalizumab therapy worsen neuromyelitis optica?Neurology, 2012
- Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorderMultiple Sclerosis Journal, 2011
- Transient increases in anti-aquaporin-4 antibody titers following rituximab treatment in neuromyelitis optica, in association with elevated serum BAFF levelsJournal of Clinical Neuroscience, 2011
- The spectrum of neuromyelitis opticaPublished by Elsevier ,2007